A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731

Status	RECRUITING
Phase	Phase 2
Sponsor	argenx
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (8)

- The participant is within the ages of 18 and 80 years old
- The participant had a kidney transplant (living or deceased donor) at least 6 months before the study
- The participant has received a diagnosis of active or chronic active antibody-mediated rejection (AMR) with detectable donor-specific antibodies at time of the study
- A participant may be allowed into the study if they receive the following medications:
- Received mycophenolate mofetil for at least 20 weeks before the study

... and 3 more (see full listing online)

Exclusion (5)

- Confirmed T-cell or mixed rejection at time of the study
- Recent change in immunosuppressive therapy agents
- Any other medical condition that, in the investigator's opinion, would interfere with the results of the study or put the participant at undue risk
- Pregnant or lactating state or intention to become pregnant during the study
- The complete list of criteria can be found in the protocol

Locations (23 total)

University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University of Chicago Medical Center, Chicago, Illinois, United States
... and 20 more locations